Recurrence of 6mm Rectal Neuroendocrine Tumor, 14 Years after Excision Abstract #1715

Introduction: Rectal neuroendocrine tumours (NET) constitute 25% of all the digestive NET. Predictive factors of distant metastasis are: size greater than 1cm, high proliferative index and muscularis or lymphovascular invasion. In the absence of these criteria, some authors advocate there is no need for long-term follow-up.
Aim(s): Highlight the malignant potential of low grade NETs and importance of follow-up.
Materials and methods: .
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide
Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Bernardo Marques
#1717 Yttrium-90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis
Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#1720 Yttrium90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis
Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola